Stuttgart
18.09.26 | 21:56
2,592 Euro
0,00 % 0,000
1-Jahres-Chart
5-Tage-Chart
| Realtime | Geld | Brief | Zeit |
|---|---|---|---|
| 2,544 | 2,716 | 19.09. | |
| 2,590 | 2,666 | 18.09. |
- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 09.09. | OSE Immunotherapeutics Welcomes First Patient Dosed by Veloxis in the Phase 2 RENGEVITY-201 Trial Evaluating Pegrizeprument (VEL-101) for the Prevention of Organ Rejection in Kidney Transplant Recipients | 570 | GlobeNewswire (Europe) | Nantes, France, September 9, 2026 - 6pm CEST - OSE Immunotherapeutics SA (ISIN: FR0012127173; Mnemo: OSE) (the "Company") welcomes the announcement by its licensee Veloxis Pharmaceuticals, Inc. that... ► Artikel lesen | |
| 28.08. | OSE Immunotherapeutics to host a KOL webcast dedicated to lusvertikimab on September 2, 2026 | 3 | GlobeNewswire (USA) | ||
| 08.07. | OSE Immunotherapeutics: Half-Year Report on Liquidity Contract with Invest Securities | 4 | GlobeNewswire (USA) | ||
| 03.06. | OSE Immunotherapeutics: Annual General Meeting on June 24, 2026 Procedures for obtaining preparatory documents for the General Meeting | 6 | GlobeNewswire (USA) | ||
| 03.06. | OSE Immunotherapeutics Reports Full Year 2025 Audited Consolidated Financial Results and Announces the Filing of its 2025 Universal Registration Document | 217 | GlobeNewswire (Europe) | 2025 Audited financial statements are consistent with Unaudited financial statements previously reported on April 30, 2026The IRIS Financing announced on May 28, 2026, was added as a subsequent eventConfirmed... ► Artikel lesen | |
| OSE IMMUNOTHERAPEUTICS Aktie jetzt für 0€ handeln | |||||
| 28.05. | OSE Immunotherapeutics to Implement a Flexible Bridge Equity Financing | 359 | GlobeNewswire (Europe) | First step of a global financing strategy, as the Company is actively engaging with institutional investors in the United States and in EuropeGross proceeds could amount to €19.3 million based on... ► Artikel lesen | |
| 22.05. | OSE Immunotherapeutics Reports Positive Topline Results of TEDOVA Phase 2 Trial with Tedopi in Recurrent Ovarian Cancer | 301 | GlobeNewswire (Europe) | OSE Immunotherapeutics Reports Positive Topline Results of TEDOVA Phase 2 Trial with Tedopi® in Recurrent Ovarian Cancer Topline results to be presented by Alexandra Leary, MD, PhD, on May 30, 2026... ► Artikel lesen | |
| 30.04. | OSE Immunotherapeutics Reports Full Year 2025 Unaudited Consolidated Financial Results and 2026 Q1 Cash Position | 484 | GlobeNewswire (Europe) | OSE entered 2026 with a clear 3-year strategic roadmap focused on delivering multiple catalysts for both lusvertikimab and Tedopi®1€22.7 and €17.0 million cash position as of December 31, 2025, and... ► Artikel lesen | |
| 27.04. | OSE Immunotherapeutics Welcomes FDA Orphan Drug Designation Granted to Pegrizeprument (VEL-101) for Prevention of Organ Rejection in Heart Transplant Patients | 387 | GlobeNewswire (Europe) | Nantes, France, April 27, 2026 - 7:30am CEST - OSE Immunotherapeutics SA (ISIN: FR0012127173; Mnemo: OSE), today welcomes the announcement by its partner Veloxis Pharmaceuticals, Inc. that the U.S.... ► Artikel lesen | |
| 23.04. | OSE Immunotherapeutics' ovarian cancer trial to be presented at ASCO | 2 | Investing.com | ||
| 23.04. | OSE Immunotherapeutics stellt Studiendaten zu Eierstockkrebs auf ASCO-Jahrestagung vor | 1 | Investing.com Deutsch | ||
| 23.04. | OSE Immunotherapeutics Announces Presentation of TEDOVA Phase 2 Topline Results of Tedopi in Ovarian Cancer at the ASCO 2026 Meeting | 2 | GlobeNewswire (USA) | ||
| 15.04. | OSE Immunotherapeutics to Present a Novel, First-in-Class, FPR2 Agonist Monoclonal Antibody in the Resolution of Chronic Inflammation at the AAI 2026 Meeting | 3 | GlobeNewswire (USA) | ||
| 14.04. | OSE Immunotherapeutics Evolves its Leadership Team | 428 | GlobeNewswire (Europe) | OSE Immunotherapeutics Evolves its Leadership Team Thomas Gidoin and Aurore Morello appointed Deputy CEO and CSO, respectively Nantes, France, April 14, 2026 - 6:00pm CEST - OSE Immunotherapeutics... ► Artikel lesen | |
| 10.03. | OSE Immunotherapeutics Confirms Marc Le Bozec as Chief Executive Officer to Lead Next Phase of Strategic Growth | 226 | GlobeNewswire (Europe) | Nantes, France, March 10, 2026 - 7:30am CET - OSE Immunotherapeutics SA (ISIN: FR0012127173; Mnemo: OSE), today announced the transition of Marc Le Bozec from interim to permanent Chief Executive... ► Artikel lesen | |
| 03.03. | OSE Immunotherapeutics - Reaffirmed dedication to core assets | 659 | Edison Investment Research | OSE Immunotherapeutics has reaffirmed its strategy of streamlining its clinical pipeline following some developments to its partnered assets. For ABBV-230 (OSE-230), partnered with AbbVie, OSE had previously... ► Artikel lesen | |
| 02.03. | OSE Immunotherapeutics Accelerates Strategic Refocusing to Advance Late Stage Value Drivers Lusvertikimab and Tedopi | 433 | GlobeNewswire (Europe) | Streamlining of selected non-strategic early-stage programs completed, consistent with previously announced three-year 2026-2028 strategic planNo impact on cash runway or financing strategy as no... ► Artikel lesen | |
| 26.02. | OSE Immunotherapeutics Receives Second Positive IDMC Recommendation for Phase 3 ARTEMIA Trial Evaluating Tedopi in Non-Small Cell Lung Cancer | 666 | GlobeNewswire (Europe) | NANTES, France, February 26, 2026 - 6pm CET - OSE Immunotherapeutics SA (ISIN: FR0012127173; Mnemo: OSE), today announced that the Independent Data Monitoring Committee (IDMC) has issued a second... ► Artikel lesen | |
| 29.01. | OSE Immunotherapeutics Selects Chronic Pouchitis and Hidradenitis Suppurativa as New Key Indications for Lusvertikimab | 287 | GlobeNewswire (Europe) | OSE Immunotherapeutics Selects Chronic Pouchitis and Hidradenitis Suppurativa as New Key Indications for Lusvertikimab Development built on strong IL-7R biological rationaleChronic Pouchitis offers... ► Artikel lesen | |
| 21.01. | OSE Immunotherapeutics Welcomes FDA Orphan Drug Designation Granted to Pegrizeprument (VEL-101) | 548 | GlobeNewswire (Europe) | OSE Immunotherapeutics Welcomes FDA Orphan Drug Designation Granted to Pegrizeprument (VEL-101) Nantes, France, January 21, 2026 - 6pm CET - OSE Immunotherapeutics SA (ISIN: FR0012127173; Mnemo: OSE)... ► Artikel lesen |
1 2 Weiter >>
30 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| BIONTECH | 83,80 | +0,18 % | BioNTech SE: Neue Daten zu Gotistobart zeigten annähernde Verdopplung des medianen Gesamtüberlebens im Vergleich zur Standardchemotherapie bei Patientinnen und Patienten mit zuvor behandeltem Plattenepithelkarzinom der Lunge | Gotistobart zeigte weiterhin Potenzial als chemotherapiefreie Monotherapie zur Reaktivierung der Anti-Tumor-Immunität in bereits vorbehandelten Patientinnen und Patienten mit Plattenepithelkarzinom... ► Artikel lesen | |
| EVOTEC | 2,914 | +1,11 % | Neue Angriffspunkte gegen Krebs! Warum Vidac Pharma, BioNTech und Evotec Aufmerksamkeit verdienen! | Krebszellen nutzen ausgeklügelte Schutzmechanismen, entziehen sich dem Immunsystem und programmieren ihren eigenen Stoffwechsel um. Diese Mechanismen werden nun verstärkt zur Zielscheibe von Biotechgesellschaften.... ► Artikel lesen | |
| BB BIOTECH | 54,90 | -0,72 % | BB Biotech: KI verändert das Wie, nicht das Was | BB Biotech verbindet seit mehr als 30 Jahren wissenschaftliche Expertise mit einem konsequenten Investmentansatz im Biotechnologiesektor. Mit künstlicher Intelligenz entwickelt das Unternehmen diesen... ► Artikel lesen | |
| MEDIGENE | 0,005 | -3,70 % | XFRA DELETION OF INSTRUMENTS FROM BOERSE FRANKFURT - 30.06.2026 | The following instruments on Boerse Frankfurt do have their last trading day on 30.06.2026Die folgenden Instrumente in Boerse Frankfurt haben ihren letzten Handelstag am 30.06.2026ISIN NameBE0003593044 COFINIMMOCA8765111064 TASEKO... ► Artikel lesen | |
| QIAGEN | 38,410 | -0,51 % | AKTIE IM FOKUS: Qiagen ziehen an - Magazinbericht schürt Übernahmefantasie | FRANKFURT (dpa-AFX) - Bei den Aktien von Qiagen hat am Donnerstag ein Magazinbericht die bereits bestehende Übernahmefantasie angeheizt. Die Aktien des Molekulardiagnostik-Unternehmens zogen am Mittag... ► Artikel lesen | |
| MODERNA | 134,16 | +0,12 % | Moderna und BioNTech lassen Corona endgültig hinter sich | Aus dem alten Duell der beiden Corona-Gewinner ist ein neuer Wettbewerb geworden. Moderna erlebt nach überzeugenden Phase-3-Daten für eine personalisierte Krebstherapie eine spektakuläre Neubewertung.... ► Artikel lesen | |
| VALNEVA | 2,863 | +1,02 % | Valneva-Aktie im Check am 19.09. (10:35 Uhr): Meine aktuelle Lageeinschätzung | ||
| AMGEN | 335,15 | -0,16 % | Amgen: FDA Approves Update To IMDELLTRA Prescribing Information, Cuts Monitoring Time For Two Doses | THOUSAND OAKS (dpa-AFX) - Amgen (AMGN) announced the FDA approved an update to the IMDELLTRA Prescribing Information that substantially reduces the recommended monitoring time for the first... ► Artikel lesen | |
| NOVAVAX | 8,670 | -1,37 % | Novavax: Langfristige Aussichten im Spannungsfeld von Innovation und Konkurrenz | ||
| STRYKER | 238,70 | -0,29 % | Stryker nach Cyberattacke: Was Anleger jetzt wissen müssen | ||
| BIOGEN | 189,04 | +0,74 % | Biogen Inc.: Phase 3 Pediatric EMPAVELI Data Published in Clinical Journal of the American Society of Nephrology Show Reduction in Proteinuria and Stabilized Kidney Function in Adolescents with C3G or Primary IC-MPGN | EMPAVELI-treated adolescents achieved a 75% relative reduction in proteinuria within 6 months versus placebo EMPAVELI is the only approved treatment for adolescents with C3G and primary IC-MPGN, based... ► Artikel lesen | |
| BIOFRONTERA | 2,360 | -3,28 % | Biofrontera erhält FDA-Zulassung für Hautkrebsbehandlung | ||
| HEIDELBERG PHARMA | 2,470 | -0,40 % | Heidelberg Pharma AG-Aktie im Check am 18.09. (08:39 Uhr): Meine aktuelle Lageeinschätzung | ||
| ILLUMINA | 210,00 | +0,70 % | Biotech Stocks At 52-Week Highs - BlossomHill Therapeutics +18% On Positive Trial Data, Adaptive Biotechnologies, Illumina, CeriBell, Neogen | SAN DIEGO (dpa-AFX) - The following biotech stocks reached a 52-week high on September 16, 2026, driven by positive results from clinical trials or an upcoming conference participation.BlossomHill... ► Artikel lesen | |
| HEMAB THERAPEUTICS | 41,190 | 0,00 % | Gubra A/S: Gubra collaboration partner Hemab announces first participant dosed in Phase 1 clinical trial of HMB-003, an investigational therapy for the management of heavy menstrual bleeding | Today, Gubra announced that its partner Hemab Therapeutics has dosed the first healthy volunteer in its Phase 1 clinical trial evaluating HMB-003, an investigational therapy for the management of heavy... ► Artikel lesen |
OSE IMMUNOTHERAPEUTICS SA gehört der Branche Biotechnologie an. Der aktuelle Kurs liegt bei 2,592 Euro und damit 0,00 % im Plus.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu OSE IMMUNOTHERAPEUTICS SA finden Sie auf Wallstreet Online.